MIAS Pharma: End to End MAH services for Virtual and Rare Disease Companies

Clinical development and launch design

The MAH’s responsibility starts long before approval. Early decisions on clinical design, target markets and labelling concepts shape future regulatory strategy, supply chain setup and pharmacovigilance. MIAS supports sponsors and virtual companies from the clinical stage by:

• Providing EU regulatory strategy for centralised, decentralised or national procedures and paediatric/rare disease incentives.
• Advising on CMC and GMP expectations so that data packages will support future marketing authorisation and variations.
• Mapping how clinical‑stage packaging, labelling and QP certification will transition into commercial MAH obligations.

By embedding MAH thinking during development, you reduce the risk of delays, refusals or costly post‑approval re‑work at the point of launch.

Supply chain design, QP/RP arrangements and continuity of supply

EU law requires the MAH to ensure an uninterrupted, compliant supply chain, including qualified manufacturing, importation and distribution sites and appropriate Qualified Person (QP) and Responsible Person (RP) oversight. MIAS acts as a one‑stop hub for:

• Designing and qualifying your EU supply chain, including importers, CMOs, packagers, and wholesalers.
• Providing experienced QP and RP services, including batch certification, oversight of GDP and coordination with local distributors.
• Establishing continuity‑of‑supply strategies, including dual sourcing, safety‑stock approaches and regulatory filing strategies to support them.

For companies without any EU entity or local headcount, MIAS effectively becomes your operational MAH arm in Europe, underpinned by quality and technical agreements with all key partners.

Labelling, packaging, complaints and falsified medicines controls

MAHs are legally accountable for the accuracy of labelling and packaging, complaint handling and quality defects, and for compliance with the Falsified Medicines Directive (FMD), including safety features and verification/serialization controls. MIAS provides:

• Artwork and labelling governance, including QRD‑compliant texts, multilingual management, artwork approval workflows and oversight of printers and packagers.
• Set‑up and ongoing management of serialization and safety‑feature controls with EMVS/NMVS connectivity, including support for vendor selection and validation.
• Complaint, quality defect and recall systems tailored to your products and territories, with clear decision‑making pathways and authority communication.

This integrated control framework allows sponsors to avoid building their own artwork, packaging, quality defect and serialization departments while still meeting full MAH expectations.

Pharmacovigilance, promotion and medical information

EU legislation requires every MAH to operate a robust pharmacovigilance (PV) system with an EU Qualified Person responsible for Pharmacovigilance (QPPV), as well as compliant promotion and medical information functions. MIAS can:

• Provide or integrate with an EU QPPV and Local Safety Officers, support the Pharmacovigilance System Master File (PSMF), and ensure signal management links to labelling changes and risk minimisation.
• Support review and approval of promotional materials so that marketing and field activities remain aligned to the SmPC and local codes.
• Operate or oversee medical information services, ensuring accurate, consistent responses to healthcare professionals and patients, and appropriate feedback into PV and quality systems.

For rare disease therapies, where patient numbers are low and stakeholders are highly specialised, MIAS’s experience with niche indications and complex access pathways is particularly valuable.

Maintenance of the MA and product discontinuation

Once a marketing authorisation is granted, the MAH’s responsibilities continue for as long as the product remains on the market. This includes variations, renewals, periodic reporting and the orderly management of any suspension or discontinuation. MIAS supports:

• Lifecycle management of the MA, including CMC and safety variations, line extensions, renewals and regulatory intelligence to anticipate changing EU requirements.
• Coordination of periodic safety/cumulative benefit–risk evaluations and downstream implementation into labelling, risk minimisation and supply chain controls.
• Structured planning and communication for product discontinuation or temporary interruptions, including obligations to inform authorities and prevent avoidable shortages.

In each phase, MIAS acts as an extension of your team—aligning regulatory, quality, supply, PV and commercial considerations so that nothing falls into the “in‑between” spaces where compliance gaps typically appear.

Why MIAS is a one‑stop MAH solution for virtual and rare disease companies

For companies without an EU footprint, building separate EU regulatory, QA, PV, supply chain, artwork and medical information teams is rarely practical or economical. The law, however, does not relax its expectations: the MAH remains fully responsible even when activities are outsourced. By delegating operational responsibilities to MIAS under well‑structured quality and technical agreements, you:

• Reduce execution risk by relying on a provider that already operates EU‑compliant systems, procedures and experienced personnel.
• Gain immediate access to an established EU presence with a trusted network of CMOs, distributors, PV providers and consultants, and working relationships with EU authorities.
• Avoid the cost and complexity of creating multiple departments and legal entities while still meeting the full spectrum of MAH obligations from clinical transition through to discontinuation.

If you are planning an EU marketing authorisation and commercial launch—especially for a rare disease or specialised product—and want the assurance of a single, accountable partner, MIAS Pharma can function as your integrated MAH platform in Europe, from strategy to day‑to‑day operations.